MentalHealthDaily

T2943 Treats Depression via Epigenetics: HDAC5 Inibitor in Hippocampus (2024 Study)

by GLOOM

Depression remains one of the most pervasive and challenging mental health conditions, affecting millions worldwide with a significant number not responding to traditional treatments. Emerging research underscores the role of histone modifications in depression, pointing towards epigenetic mechanisms as potential targets for novel antidepressants. Specifically, a compound known as T2943 (a histone deacetylase-5 (HDAC5) inhibitor), …

Caffeine & Depression: Lower Risk with >90 mg per Day in Adults (2022 Study)

by GLOOM

In the quest to understand the intricate links between our dietary habits and mental health, a recent study leveraging data from the National Health and Nutrition Examination Survey (NHANES) 2017-2018 offers new insights into how caffeine consumption correlates with depression. This comprehensive analysis reveals that moderate caffeine intake might have a protective effect against depression, …

Zuranolone for Depression: Rapid Efficacy & Safety in Clinical Trials (2023 Review)

by GLOOM

Zuranolone, a novel antidepressant, shows promise in treating depression, as evidenced by a recent meta-analysis. A new study investigated zuranolone’s efficacy and safety, focusing on short-term rapid antidepressant effects. Highlights: Zuranolone Effectiveness: Demonstrated significant improvement in depression severity scores compared to placebo, with notable effects by day 15. Treatment-Emergent Adverse Events (TEAEs): Increased incidence in …

SSRI-Induced Sexual Dysfunction Reversed with “Drug Holidays” on Weekends (2024 Study)

by GLOOM

Selective serotonin reuptake inhibitors (SSRIs) are a mainstay in the treatment of various mental disorders but often come with the unwelcome side effect of sexual dysfunction. This issue can significantly affect patients’ adherence to their medication regime, often leading to treatment discontinuation. A recent clinical trial offers a new perspective, suggesting that ‘drug holidays’ – …

Pharmacogenomics (PGx) for Depression: Genetic Analysis to Amplify Antidepressant Efficacy? (2023 Review)

by GLOOM

Depression, a leading cause of disability globally, often presents challenges in treatment due to the variability in individual responses to antidepressants. Pharmacogenomic (PGx) testing, an approach aligning treatment with genetic makeup, promises to tailor depression therapy more effectively. Highlights: Major Depressive Disorder (MDD) impacts a significant portion of the global population, with traditional treatments often …

Psilocybin for Major Depression in Adults (2023 Evidence Review)

by GLOOM

The emerging research into psilocybin, a classical psychedelic, reveals its significant potential in treating Major Depressive Disorder (MDD). Historically used in spiritual and shamanic practices, psilocybin’s recent clinical studies have opened new avenues in mental health treatment, challenging traditional antidepressants like SSRIs. Highlights: Psilocybin’s Historical & Clinical Relevance: A natural compound used for millennia, recent …

Esketamine Nasal Spray Effective Last Resort for Treatment-Resistant Depression (TRD)? (2023 Study)

by GLOOM

Treatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail. Recent studies, including a prospective, observational study at a leading medical center, have brought new hope in the form of esketamine, a novel antidepressant. Highlights: Esketamine’s Mechanism: Esketamine, the S-enantiomer of …